Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with... BioDrugs (2017) 31:369–377 DOI 10.1007/s40259-017-0233-6 OR IGINAL RESEARCH ARTIC L E Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis 1 2 3 4 • • • • Won Park Chang-Hee Suh Seung Cheol Shim Francisco Fidencio Cons Molina 5 6 7 • • • Slawomir Jeka Francisco G. Medina-Rodriguez Pawel Hrycaj 8 9 10 11 • • • • Piotr Wiland Eun Young Lee Pavel Shesternya Volodymyr Kovalenko 12 13 14 • • • Leysan Myasoutova Marina Stanislav Sebastiao Radominski 1 15 16 16 • • • • Mie Jin Lim Jung-Yoon Choe Sang Joon Lee Sung Young Lee 16 17 Sung Hwan Kim Dae Hyun Yoo Published online: 9 June 2017 The Author(s) 2017. This article is an open access publication Abstract the RCT and switched to CT-P10 during the OLE (‘switch Background CT-P10 is a biosimilar candidate of innovator group’). rituximab (RTX) that demonstrated a comparable clinical Methods Patients who completed the RCT were recruited. profile to RTX in a phase I randomized controlled trial Based on the Disease Activity Score using 28 joints (RCT) in rheumatoid http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BioDrugs Springer Journals

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis

Loading next page...
 
/lp/springer-journals/efficacy-and-safety-of-switching-from-innovator-rituximab-to-nB7Npa4YpK
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Biomedicine; Molecular Medicine; Antibodies; Cancer Research; Pharmacotherapy
ISSN
1173-8804
eISSN
1179-190X
D.O.I.
10.1007/s40259-017-0233-6
Publisher site
See Article on Publisher Site

Abstract

BioDrugs (2017) 31:369–377 DOI 10.1007/s40259-017-0233-6 OR IGINAL RESEARCH ARTIC L E Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis 1 2 3 4 • • • • Won Park Chang-Hee Suh Seung Cheol Shim Francisco Fidencio Cons Molina 5 6 7 • • • Slawomir Jeka Francisco G. Medina-Rodriguez Pawel Hrycaj 8 9 10 11 • • • • Piotr Wiland Eun Young Lee Pavel Shesternya Volodymyr Kovalenko 12 13 14 • • • Leysan Myasoutova Marina Stanislav Sebastiao Radominski 1 15 16 16 • • • • Mie Jin Lim Jung-Yoon Choe Sang Joon Lee Sung Young Lee 16 17 Sung Hwan Kim Dae Hyun Yoo Published online: 9 June 2017 The Author(s) 2017. This article is an open access publication Abstract the RCT and switched to CT-P10 during the OLE (‘switch Background CT-P10 is a biosimilar candidate of innovator group’). rituximab (RTX) that demonstrated a comparable clinical Methods Patients who completed the RCT were recruited. profile to RTX in a phase I randomized controlled trial Based on the Disease Activity Score using 28 joints (RCT) in rheumatoid

Journal

BioDrugsSpringer Journals

Published: Jun 9, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off